Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody™), in metastatic castration resistant prostate cancer patients
American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) San Francisco, CA February 16-18, 2023.